SHORTAGE OF GAME OFFICIALS. MILLIONS OF PEOPLE ARE USING INJECTABLE MEDICATION TO TRY AND LOSE WEIGHT. HERE TO TALK ABOUT THAT IS DOCTOR TODD ELLERIN ACTING CHIEF OF MEDICINE AT SOUTH SHORE HEALTH. GOOD TO SEE YOU, DOCTOR. HEY, DR. T, IT’S GREAT TO SEE YOU SO IF I PUT YOU THE NAMES, HELP ME HERE. BUT THE THREE MOST COMMON BRAND NAMES ARE OZEMPIC, WHERE V AND MAGARO. BUT THEY AREN’T ACTUALLY MEANT FOR WEIGHT LOSS. THEY’RE MEANT TO TREAT DIABETES. SO HOW ARE PEOPLE WHO AREN’T DIABETIC GETTING IT ALL RIGHT, SO LET ME JUST TWEAK THAT A LITTLE BIT. SO OZEMPIC AND MUNJAL ARE DIABETIC MEDICATIONS. OKAY. WE’RE GOVI IS A WEIGHT LOSS MEDICATION NOW, THE DIFFERENCE BETWEEN OZEMPIC AND GOVI IS REALLY JUST THE DOSAGE. OKAY, WE’LL GO TO THESE HIGHER DOSAGE. SO WHAT THEY FOUND IS THESE TYPE OF MEDICAL ACTIONS THAT ARE VERY ACTIVE AND EFFECTIVE AT HELPING DIABETICS. WHAT SCIENTISTS AND CLINICIANS HAVE SEEN IS THERE’S ALSO WEIGHT LOSS. OKAY. AND SO THE PHARMACEUTICAL COMPANIES HAVE TAKEN ADVANTAGE OF THAT. AND ARE NOW LOOKING AT THESE FOR CHRONIC WEIGHT LOSS AND WHAT WAS THE FIRST FDA APPROVED MEDICATION ABOUT TWO YEARS AGO NOW. AND AND MUJURU, WHICH YOU HAD MENTIONED, THAT’S ACTUALLY THE FDA IS TRYING TO FAST TRACK THAT FOR APPROVAL. GOT IT. BUT HOW ARE PEOPLE GETTING IT? YEAH, WELL, REMEMBER, IF YOU’RE USING GOVI, THAT’S BEEN APPROVED FOR PATIENTS WHO ARE OBESE, THAT MEANS A BMI, A BODY MASS INDEX OF 30 OR MORE, OR THOSE WHO ARE OVERWEIGHT, BUT ALSO HAVE ADDITIONAL RISK FACTORS LIKE HIGH BLOOD PRESSURE AND DIABETES. SO YOU CAN GET IT THROUGH INSURANCE. OF COURSE, SOME PEOPLE, SOME CLINICIANS ARE ARE PRESCRIBED IT WHAT WE CALL OFF LABEL. SO IT MAY NOT BE FOR A DIABETIC. AND AND THAT’S WHEN WE HAVE TO REALLY JUST BE CAREFUL BECAUSE WE WANT TO MAKE SURE THAT THESE MEDICATIONS ARE THERE FOR THE DIABETICS AND WE WANT TO MAKE SURE THOSE THE MEDICATIONS ARE THERE FOR THE OBESE PATIENTS. SO IF YOU JUST WANT TO LOSE A FEW POUNDS, THIS IS NOT THE RIGHT MEDICATION BECAUSE THEN THAT HURTS THE EQUITY PIECE. RIGHT. BECAUSE SOME OF THE PEOPLE THAT ARE THE MOST OBESE ARE ALSO THE POOREST, DON’T HAVE ACCESS TO GYMS, DON’T NECESSARILY HAVE ACCESS TO THAT HEALTHY FOOD. SO THESE ARE SUPPOSED TO BE USED IN CONJUNCTION. SO THE MEDICATIONS. DR. T WORK BY SUPPRESSING A PERSON’S APPETITE, RIGHT? MAKING THEM FEEL FULL. IF, YOU KNOW, JUST A BASIC QUESTION, IS THAT A SAFE WAY TO LOSE WEIGHT? YEAH, IT’S A IT’S A FAIR OBSERVATION. I WILL SAY IN GENERAL, I’LL SAY YES. NOW, REMEMBER A FEW THINGS. WEIGHT LOSS OF ABOUT 5 TO 10% OF TOTAL WEIGHT CAN GREATLY REDUCE YOUR RISK OF DIABETES. IF YOU’RE PRE-DIABETIC. IT CAN REDUCE YOUR BLOOD PRESSURE. IT CAN REDUCE YOUR RISK OF CARDIOVASCULAR DISEASE. SO THESE ARE REALLY IMPORTANT. BUT IT’S TRUE THAT, YOU KNOW, YOU WANT TO MAKE SURE THAT YOU’RE GETTING THIS TO THE RIGHT PERSON. AND AND THERE ALSO CAN BE SIDE EFFECTS AS WELL. AND I THINK AND WE’LL TALK ABOUT THAT. WELL, LET’S TALK ABOUT THAT. YEAH. WHAT KIND OF SIDE EFFECTS RIGHT. SO SO NAUSEA AND VOMITING OR GASTROINTESTINAL SIDE EFFECTS ARE COMMON. THERE ARE CONTRAINDICATED ACTIONS TO THESE. IF YOU HAVE A HISTORY OF PANCREATIC TITUS, OR IF YOU HAVE A HISTORY OF THYROID CANCER, A SPECIFIC TYPE OF THYROID CANCER, THEN YOU DON’T WANT TO USE THESE MEDICATIONS. I THINK OVERALL, WHAT I WANT TO EMPHASIZE AT THIS IS ONE AT ADJUNCT TO WEIGHT LOSS. WEIGHT LOSS INCLUDES HEALTHY FOOD IS THE MOST IPORTANT. PHYSICAL ACTIVITY IS IMPORTANT BEHAVIOR MODIFICATION AS WELL. THIS THIS IS USED IN CONJUNCTION. AND REMEMBER ONCE YOU START THESE INJECTIONS AND THESE ARE INJECTIONS, THAT’S ANOTHER, YOU KNOW, SIDE EFFECT. YOU CAN SAY IS INJECTION SITE REACTIONS. BUT ONCE YOU START IT, YOU YOU YOU CAN LOSE UP TO A CERTAIN AMOUNT OF WEIGHT. ONCE YOU’VE ACHIEVED THAT MAXIMAL AMOUNT, THEN YOU PLATEAU. IT DOESN’T MEAN IT DOESN’T IT DOESN’T MEAN IT STOPPED WORKING. IT JUST MEANS YOU’RE NOT GOING TO LOSE ANY MORE WEIGHT. BUT REMEMBER, PEOPLE WHO STOP THESE MEDICATIONS ABOUT YOU GAIN ABOUT TWO THIRDS OF THE WEIGHT. YOU LOST BACK AT ABOUT ONE YEAR. SO IT’S LIKE ANYTHING ELSE, WE HAVE TO KEEP ON IT FOR IT TO CONTINUE TO WORK. ALL RI
In a lawsuit filed on Wednesday, a Louisiana lady is claiming she has suffered extreme accidents because of her use of Ozempic and Mounjaro, which have been prescribed by her physician. The 2 injectable drugs, developed to handle diabetes, have gained recognition for weight reduction. Attorneys for Jaclyn Bjorklund declare that the 44-year-old lady used Ozempic for greater than a 12 months till round July 2023 after which started utilizing Mounjaro. She is suing the makers of each medication, Novo Nordisk and Eli Lilly, for failing to warn of the chance of extreme gastrointestinal occasions that could possibly be attributable to taking the drugs.”On account of utilizing Defendants’ Ozempic and Mounjaro, Plaintiff was prompted to undergo from extreme gastrointestinal occasions, and consequently sustained extreme and everlasting private accidents, ache, struggling, and emotional misery, and incurred medical bills,” the lawsuit alleges.Bjorklund has suffered from “extreme vomiting, abdomen ache, gastrointestinal burning, being hospitalized for abdomen points on a number of events together with visits to the emergency room, tooth falling out because of extreme vomiting, requiring extra drugs to alleviate her extreme vomiting, and throwing up entire meals hours after consuming,” it provides. The lawsuit claims that the 2 firms, Novo Nordisk and Eli Lilly, “knew of the affiliation between using GLP-1 receptor agonists and the chance of growing extreme gastrointestinal points, together with gastroparesis and gastroenteritis.”Their “failure to reveal info that they possessed relating to the affiliation between using GLP-1 receptor agonists and the chance of growing extreme gastrointestinal points, together with gastroparesis and gastroenteritis, rendered the warnings for this remedy insufficient,” it continues. Vomiting and stomach ache are each listed as potential antagonistic occasions on prescribing info for Ozempic and Mounjaro, and the lawsuit doesn’t say whether or not Bjorklund was recognized with gastroparesis — abdomen paralysis. The lawsuit is looking for compensatory and punitive damages for previous and future ache and struggling Bjorklund can have together with well being care prices and medical monitoring in addition to her legal professional’s charges and courtroom prices. Novo’s Ozempic and an analogous drug, Wegovy, make the most of the identical remedy, semaglutide. Eli Lilly’s Mounjaro makes use of tirzepatide. These and different medication on this household, which incorporates drugs like liraglutide, work by mimicking a hormone that is naturally made by the physique, GLP-1, that slows the passage of meals via the abdomen, which helps individuals really feel fuller longer.Individually from the brand new lawsuit, CNN has reported on warnings from sufferers and medical doctors of gastroparesis and different unwanted effects after taking Wegovy and Ozempic for weight reduction or diabetes.Abdomen paralysis, or the slowing of the abdomen from emptying, might result in nausea and vomiting in some sufferers. It will probably have many causes, together with diabetes, which is a cause many individuals take medication. Ladies are identified to be at larger danger for the situation. Medical doctors informed CNN that extra instances are coming to gentle as the recognition of the medication has soared. In a press release earlier than the lawsuit, the U.S. Meals and Drug Administration informed CNN it had “acquired experiences of gastroparesis with semaglutide and liraglutide, a few of which documented the antagonistic occasion as not recovered after discontinuation of the respective product on the time of the report.” Video beneath: All the things you have to find out about new breakthrough weight reduction drugsOzempic’s prescribing info says the most typical antagonistic occasions associated to the drug are nausea, vomiting, diarrhea, stomach ache and constipation. Beneath a bit on drug interactions, it says that Ozempic delays gastric emptying, which can affect absorption of oral drugs. Mounjaro’s prescribing info additionally says nausea, diarrhea, decreased urge for food, vomiting, constipation, dyspepsia, and stomach ache are the most typical antagonistic occasions, and that Mounjaro delays gastric emptying, which can affect remedy absorption. In a press release to CNN responding to abdomen paralysis issues previous to the lawsuit, Novo Nordisk, the maker of Ozempic and Wegovy, mentioned, “Gastrointestinal (GI) occasions are well-known unwanted effects of the GLP-1 class. For semaglutide, nearly all of GI unwanted effects are delicate to reasonable in severity and of quick period. GLP-1’s are identified to trigger a delay in gastric emptying, as famous within the label of every of our GLP-1 RA drugs. Signs of delayed gastric emptying, nausea and vomiting are listed as unwanted effects.”Responding to the brand new lawsuit, a spokesperson for Novo Nordisk informed The Hill, “Affected person security is of utmost significance to Novo Nordisk. “We’re repeatedly monitoring the protection profile of our merchandise and collaborate intently with authorities to make sure affected person security, together with ample info on gastrointestinal unwanted effects within the label.”In a press release obtained by The Hill, a spokesperson for Eli Lilly, maker of Mounjaro, mentioned that affected person security is the corporate’s “prime precedence,” and that they “actively have interaction in monitoring, evaluating and reporting security info for all our medicines,” the information outlet reported.CNN has reached out to each Novo Nordisk and Eli Lilly for touch upon the lawsuit.
In a lawsuit filed on Wednesday, a Louisiana lady is claiming she has suffered extreme accidents because of her use of Ozempic and Mounjaro, which have been prescribed by her physician. The 2 injectable drugs, developed to handle diabetes, have gained recognition for weight reduction.
Attorneys for Jaclyn Bjorklund declare that the 44-year-old lady used Ozempic for greater than a 12 months till round July 2023 after which started utilizing Mounjaro. She is suing the makers of each medication, Novo Nordisk and Eli Lilly, for failing to warn of the chance of extreme gastrointestinal occasions that could possibly be attributable to taking the drugs.
“On account of utilizing Defendants’ Ozempic and Mounjaro, Plaintiff was prompted to undergo from extreme gastrointestinal occasions, and consequently sustained extreme and everlasting private accidents, ache, struggling, and emotional misery, and incurred medical bills,” the lawsuit alleges.
Bjorklund has suffered from “extreme vomiting, abdomen ache, gastrointestinal burning, being hospitalized for abdomen points on a number of events together with visits to the emergency room, tooth falling out because of extreme vomiting, requiring extra drugs to alleviate her extreme vomiting, and throwing up entire meals hours after consuming,” it provides.
The lawsuit claims that the 2 firms, Novo Nordisk and Eli Lilly, “knew of the affiliation between using GLP-1 receptor agonists and the chance of growing extreme gastrointestinal points, together with gastroparesis and gastroenteritis.”
Their “failure to reveal info that they possessed relating to the affiliation between using GLP-1 receptor agonists and the chance of growing extreme gastrointestinal points, together with gastroparesis and gastroenteritis, rendered the warnings for this remedy insufficient,” it continues.
Vomiting and stomach ache are each listed as potential antagonistic occasions on prescribing info for Ozempic and Mounjaro, and the lawsuit doesn’t say whether or not Bjorklund was recognized with gastroparesis — abdomen paralysis.
The lawsuit is looking for compensatory and punitive damages for previous and future ache and struggling Bjorklund can have together with well being care prices and medical monitoring in addition to her legal professional’s charges and courtroom prices.
Novo’s Ozempic and an analogous drug, Wegovy, make the most of the identical remedy, semaglutide. Eli Lilly’s Mounjaro makes use of tirzepatide. These and different medication on this household, which incorporates drugs like liraglutide, work by mimicking a hormone that is naturally made by the physique, GLP-1, that slows the passage of meals via the abdomen, which helps individuals really feel fuller longer.
Individually from the brand new lawsuit, CNN has reported on warnings from sufferers and medical doctors of gastroparesis and different unwanted effects after taking Wegovy and Ozempic for weight reduction or diabetes.
Abdomen paralysis, or the slowing of the abdomen from emptying, might result in nausea and vomiting in some sufferers. It will probably have many causes, together with diabetes, which is a cause many individuals take medication. Ladies are identified to be at larger danger for the situation.
Medical doctors informed CNN that extra instances are coming to gentle as the recognition of the medication has soared. In a press release earlier than the lawsuit, the U.S. Meals and Drug Administration informed CNN it had “acquired experiences of gastroparesis with semaglutide and liraglutide, a few of which documented the antagonistic occasion as not recovered after discontinuation of the respective product on the time of the report.”
Video beneath: All the things you have to find out about new breakthrough weight reduction medication
Ozempic’s prescribing info says the most typical antagonistic occasions associated to the drug are nausea, vomiting, diarrhea, stomach ache and constipation. Beneath a bit on drug interactions, it says that Ozempic delays gastric emptying, which can affect absorption of oral drugs.
Mounjaro’s prescribing info additionally says nausea, diarrhea, decreased urge for food, vomiting, constipation, dyspepsia, and stomach ache are the most typical antagonistic occasions, and that Mounjaro delays gastric emptying, which can affect remedy absorption.
In a press release to CNN responding to abdomen paralysis issues previous to the lawsuit, Novo Nordisk, the maker of Ozempic and Wegovy, mentioned, “Gastrointestinal (GI) occasions are well-known unwanted effects of the GLP-1 class. For semaglutide, nearly all of GI unwanted effects are delicate to reasonable in severity and of quick period. GLP-1’s are identified to trigger a delay in gastric emptying, as famous within the label of every of our GLP-1 RA drugs. Signs of delayed gastric emptying, nausea and vomiting are listed as unwanted effects.”
Responding to the brand new lawsuit, a spokesperson for Novo Nordisk informed The Hill, “Affected person security is of utmost significance to Novo Nordisk. “We’re repeatedly monitoring the protection profile of our merchandise and collaborate intently with authorities to make sure affected person security, together with ample info on gastrointestinal unwanted effects within the label.”
In a press release obtained by The Hill, a spokesperson for Eli Lilly, maker of Mounjaro, mentioned that affected person security is the corporate’s “prime precedence,” and that they “actively have interaction in monitoring, evaluating and reporting security info for all our medicines,” the information outlet reported.
CNN has reached out to each Novo Nordisk and Eli Lilly for touch upon the lawsuit.
